KALA BIO (KALA) Projected to Post Quarterly Earnings on Friday

KALA BIO (NASDAQ:KALA) is anticipated to announce its earnings results before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($2.28) per share for the quarter.

KALA BIO Stock Down 3.8 %

KALA stock opened at $6.32 on Friday. The company’s 50 day moving average price is $7.72 and its 200 day moving average price is $6.80. The firm has a market capitalization of $38.50 million, a price-to-earnings ratio of -0.51 and a beta of -2.19. KALA BIO has a fifty-two week low of $4.21 and a fifty-two week high of $11.20. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.15 and a current ratio of 2.15.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of KALA BIO in a research report on Thursday, February 13th.

Insider Buying and Selling at KALA BIO

In other KALA BIO news, major shareholder Bros. Advisors Lp Baker purchased 310,559 shares of the stock in a transaction that occurred on Monday, December 30th. The stock was purchased at an average cost of $6.44 per share, with a total value of $1,999,999.96. Following the completion of the acquisition, the insider now directly owns 1,083,398 shares of the company’s stock, valued at $6,977,083.12. This trade represents a 40.18 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Mark T. Iwicki sold 5,779 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $7.63, for a total transaction of $44,093.77. Following the sale, the chief executive officer now directly owns 280,076 shares in the company, valued at approximately $2,136,979.88. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 9,506 shares of company stock worth $72,531 over the last ninety days. Corporate insiders own 8.32% of the company’s stock.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.